Key result
MS-551 prolonged the effective refractory period in both the endocardium and epicardium during myocardial ischemia without affecting regional myocardial blood flow or increasing transmural dispersion of refractoriness.
Why the study?
Does MS-551, compared to disopyramide and propranolol, improve electrophysiological parameters and blood flow in a canine model of acute myocardial ischemia?
Does MS-551, compared to disopyramide and propranolol, improve electrophysiological parameters and blood flow in a canine model of acute myocardial ischemia?
MS-551 may have a more favorable electrophysiological profile than disopyramide and propranolol in acute myocardial ischemia by prolonging refractoriness without increasing its dispersion.
May inform ischemia-targeted antiarrhythmic development; leaves open clinical translation from this canine model.
No takes yet. Share an insight, caveat, or question.
Iwamoto et al. (1997) studied Myocardial ischemia (n=50). Antiarrhythmic agents (Disopyramide, Propranolol, MS-551) vs. Saline (control) was evaluated on Endo- and epicardial effective refractory periods (ERP) and regional myocardial blood flow. MS-551 prolonged the effective refractory period in both the endocardium and epicardium during myocardial ischemia without affecting regional myocardial blood flow or increasing transmural dispersion of refractoriness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: